This is a working overview of chronic hepatitis B, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-02. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Supramolecular chemistry is the branch of chemistry concerning chemical systems composed of discrete numbers of molecules. The strength of the forces responsible for spatial organization of the system ranges from weak intermolecular forces, electrostatic charge, or hydrogen bonding to strong covalent bonding, provided that the electronic coupling strength remains small relative to the energy parameters of the component. While traditional chemistry concentrates on the covalent bond, supramolecular chemistry examines the weaker and reversible non-covalent interactions between molecules. These forces include hydrogen bonding, metal coordination, hydrophobic forces, van der Waals forces, pi–pi interactions and electrostatic effects. Important concepts advanced by supramolecular chemistry include molecular self-assembly, molecular folding, molecular recognition, host–guest chemistry, mechanically-interlocked molecular architectures, and dynamic covalent chemistry. The study of non-covalent interactions is crucial to understanding many biological processes that rely on these forces for structure and function. Biological systems are often the inspiration for supramolecular research.
In early 2002, Boston Market entered the Australian market, opening nine stores in the Sydney metropolitan area by 2004, before converting some stores to McDonald's and quietly exiting the Australian market later that year due to competitive pressures. In April 2004, Boston Market introduced chilled menu items to be sold in supermarkets. In December 2005, these chilled menu items were available in 700 supermarkets. In 2005, Boston Market also started limited-time offers, such as Crispy Country Chicken, an oven-baked chicken breast with gravy. In 2007, McDonald's announced that it was "exploring strategic options" for the subsidiary. On August 6, 2007, McDonald's announced plans to sell the chain to Sun Capital Partners, a transaction that was completed on August 27, 2007. In 2013, Boston Market opened its first new location in seven years in Florida and in 2015 it added ribs to the menu.
== Clinical significance == LRRC15 is aberrantly expressed in cancer. It is highly expressed in CAFs within the stroma of numerous solid tumors and directly expressed in mesenchymal tumors such as glioblastoma, sarcomas, and melanoma. Preliminary evidence indicates that expression may be related to the severity of COVID-19. and that it is an inhibitory accessory factor for SARS-CoV-2 cell entry.
Sources: en.wikipedia.org
Pevehouse, Jon C. W., Timothy Nordstron, Roseanne W. McManus, Anne Spencer Jamison (2020). "Tracking Organizations in the World: The Correlates of War IGO Version 3.0 datasets." Journal of Peace Research, 57(3), 492–503. https://www.jstor.org/stable/48596260. Roger, Charles, Sam Rowan, "The New Terrain of Global Governance: Mapping Membership in Informal International Organizations", Journal of Conflict Resolution, 67 (6): 281–310. Lundgren, Magnus, Theresa Squatrito, Thomas Sommerer, Jonas Tallberg (2023). "Introducing the Intergovernmental Policy Output Dataset (IPOD)". The Review of International Organizations 19, 117–146 (2024). https://doi.org/10.1007/s11558-023-09492-6. Eilstrup-Sangiovanni, Mette (March 2021). "What kills international organisations? When and why international organisations terminate". European Journal of International Relations. 27 (1).
=== Abnormal folate metabolism === Several lines of evidence indicate abnormalities of folate metabolism in ASD. These abnormalities can lead to a decrease in 5-methyltetrahydrofolate production, alter the production of folate metabolites and reduce folate transport across the blood-brain barrier and in neurons. The most significant abnormalities of folate metabolism associated with ASD may be autoantibodies to the alpha folate receptor (FRα). These autoantibodies have been associated with cerebral folate deficiency. Autoantibodies can bind to FRα and greatly impair its function. In 2013, one study reported that 60% and 44% of 93 children with ASD were positive for FRα-blocking and binding autoantibodies, respectively. This high rate of anti-FRα autoantibody positivity was confirmed by Ramaekers et al. who compared 75 children with ASD to 30 non-autistic "controls". These controls were children who had a developmental delay, but did not have ASD. FRα-blocking autoantibodies were positive in 47% of children with ASD, but only in 3% of children without ASD. The authors of this study (RE Frye, JM Sequeira, EV Quadros, SJ James and DA Rossignol) have contributed to other such studies on FRα autoantibodies with similar results, however are considered to have a conflict of interest by the publishers. Many children with ASD and cerebral folate deficiency have marked improvements in their clinical status when taking folinic acid.
=== Critical response === On Rotten Tomatoes, the first season holds an approval rating of 72% based on 64 reviews. On Metacritic, the season has a weighted average score of 64 out of 100 based on 31 critics, which the site categorizes as "generally favorable reviews." Some reviewers drew unfavorable comparisons to Coralie Fargeat's 2024 film The Substance, which had explored similar themes of body horror and beauty culture the prior year. Writing for IndieWire, Ben Travers described the series as a "misshapen mess" and a "feeble spin" on The Substance. The review on RogerEbert.com argued the series had "so much style and very little substance" and did not go sufficiently deep into its central ideas. Tech Advisor similarly described the series as "messy and pretentious" and "not entertaining enough for a decent guilty pleasure." Writing for Bloody Disgusting, Daniel Kurland called it a "botched, ugly embarrassment," acknowledging the show's practical effects as "genuinely remarkable" but arguing that its satire grows "increasingly repetitive and meandering" and that its final act "transforms it into an almost completely different series."
Sources: en.wikipedia.org
In the Constituent Assembly of India debates between 1946 and 1949, India's founders strongly preferred birthplace citizenship, viewing it as more democratic than basing rights on race or descent. While India’s 1950 constitution originally offered palliative measures to those displaced by the Partition, the Citizenship Act of 1955 formally established birthplace as the foundation for Indian citizenship. More recently, India's new citizenship laws have shifted to favour bloodline over birthplace, creating legal obstacles for new or marginalised groups to experience substantive equality. The Lok Sabha, India’s lower house of parliament, has 543 members directly elected by citizens aged 18 and older, with specific seats reserved to ensure fair representation for Scheduled Castes and Scheduled Tribes. However, its legislative productivity has significantly declined over the decades, with the average number of working days dropping from 121 days per year in the 1950s to 68 days between 2000 and 2023. In addition, more meeting time is lost to disruptions. The Rajya Sabha, India’s upper house of parliament, serves as a federal chamber where state legislatures elect members through a system that balances state size with minimum representation for smaller regions. However, historical data shows that most members serve only a single term, suggesting that political party leaders sometimes use these seats to reward favourites.
== Books == Seven and a Half Lessons About the Brain. Houghton Mifflin Harcourt, 2020. ISBN 0358157145. How Emotions are Made: The Secret Life of the Brain. Houghton Mifflin Harcourt, 2017. ISBN 0544133315. Handbook of Emotions, Fourth Edition. Guilford Fubn, 2018 The Psychological Construction of Emotion, Guilford Fubn, 2014
== Notation == Protein sequence is typically notated as a string of letters, listing the amino acids starting at the amino-terminal end through to the carboxyl-terminal end. Either a three letter code or single letter code can be used to represent the 22 naturally encoded amino acids, as well as mixtures or ambiguous amino acids (similar to nucleic acid notation). Peptides can be directly sequenced, or inferred from DNA sequences. Large sequence databases now exist that collate known protein sequences.
The Coomassie Blue G250 dye used to bind to the proteins in the original Bradford method readily binds to arginine and lysine groups of proteins. This is a disadvantage because the preference of the dye to bind to these amino acids can result in a varied response of the assay between different proteins. Changes to the original method, such as increasing the pH by adding NaOH or adding more dye have been made to correct this variation. Although these modifications result in a less sensitive assay, a modified method becomes sensitive to detergents that can interfere with sample.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.